Avicanna

Toronto, Canada Founded: 2016 • Age: 10 yrs
Plant-derived cannabinoid products are developed for medical and consumer uses.
Annual revenue $17.7M Latest available
Total funding $5.9M 19 rounds
Employees 55 Tracked headcount
Investors 3 Known backers
Products 3 Services tracked
Competitors 8 Brand Intelligence

About Avicanna

Avicanna is a company based in Toronto (Canada) founded in 2016 by Aras Azadian. Avicanna has raised $5.94 million across 19 funding rounds from investors including Tasly, Orthogonal Thinker and Barn Invest. The company has 55 employees as of December 31, 2024. Avicanna offers products and services including Medical Cannabis Products, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients. Avicanna operates in a competitive market with competitors including ZYUS Life Sciences, Sanity Group, Terraflos, Little Green Pharma and IMCannabis, among others.

  • Headquarter Toronto, Canada
  • Employees 55 as on 31 Dec, 2024
  • Founders Aras Azadian
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Avicanna Inc
Operational Areas
Healthcare → Health Technology & Digital Health Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $17.7 M (USD)
    51.62
    as on Dec 31, 2024
  • Net Profit
    -$2.35 M (USD)
    57.19
    as on Dec 31, 2024
  • EBITDA
    -$2.16 M (USD)
    54.95
    as on Dec 31, 2024
  • Total Equity Funding
    $5.94 M (USD)

    in 19 rounds

  • Latest Funding Round
    $220.35 K (USD), Post-IPO

    Feb 10, 2026

  • Investors
    Tasly

    & 2 more

  • Employee Count
    55

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Avicanna

Avicanna is a publicly listed company on the TSX with ticker symbol AVCN in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: TSX · Ticker: AVCN · Sector: Health technology · Canada

Products & Services of Avicanna

Avicanna offers a comprehensive portfolio of products and services, including Medical Cannabis Products, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients.

Product name locked
Category locked
Primary

Evidence-based cannabinoid formulations for medical use.

Product name locked
Category locked
Locked

Developing cannabinoid-based drugs for health applications.

Product name locked
Category locked
Locked

Cannabinoid ingredients for commercial pharmaceutical products.

People of Avicanna

Headcount 10-50
Employee Profiles 13
Board Members and Advisors 11
Employee Profiles
People
Ivana Maric
EVP of Marketing
People
Aras Azadian
Co-founder and CEO
People
Samantha Watt
VP of Scientific Affairs
People
Karolina Urban
VP, Scientific & Medical Affairs

Unlock access to complete

Board Members and Advisors
people
Chandra Panchal
Chairman
people
Mauricio Torres-Pradilla
Scientific Advisor
people
Eileen McCormack
Director
people
John McVicar
Director

Unlock access to complete

Funding Insights of Avicanna

Avicanna has successfully raised a total of $5.94M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $220.35 thousand completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Avicanna

Avicanna has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Tasly, Orthogonal Thinker and Barn Invest.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
PE firm & investment bank focused on plant science based companies
Locked Locked Locked
Barn Invest is focused on greentech investments in Latin America.
Locked Locked Locked
Traditional Chinese medicines are manufactured and distributed globally.
Locked Locked Locked
Premium access

Investor details for Avicanna

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Avicanna

Investments
Premium access

Investment portfolio details for Avicanna

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Avicanna

Premium access

Detailed financials for Avicanna

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Avicanna Comparisons

Avicanna Primary company
Description
Plant-derived cannabinoid products are developed for medical...
Location
Toronto, Canada
Founded Year
2016
Annual Revenue
$17.7 M (USD)
Net Profit
-$2.35 M (USD)
EBITDA
-$2.16 M (USD)
Employees
55
As of 2024
Premium access

Peer comparison for Avicanna

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Avicanna

Avicanna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ZYUS Life Sciences, Sanity Group, Terraflos, Little Green Pharma and IMCannabis, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Cannabis-derived therapeutics for multiple indications are developed.
Locked Locked Locked
Developer of cannabinoid-based pharmaceuticals and well-being products
Locked Locked Locked
Medical cannabis products are provided based on GMP processes.
Locked Locked Locked
Manufacturer of medicinal cannabis for therapeutic use
Locked Locked Locked
Developer of medical cannabis products
Premium access

Detailed competitors of Avicanna

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Avicanna

Premium access

Complete news archive for Avicanna

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Avicanna

Avicanna was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Avicanna is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.

Aras Azadian is the current CEO of Avicanna. They have also founded this company.

Avicanna is a funded company, having raised a total of $5.94M across 19 funding rounds to date.

As of Dec 31, 2024, the latest employee count at Avicanna is 55.

Annual revenue of Avicanna is $17.7M as on Dec 31, 2024.

Avicanna was founded in 2016 in Toronto, Canada, as a developer in the cannabinoid sector. Advanced formulations and delivery systems based on plant-derived cannabinoids are created for medical applications and consumer goods. Solutions are marketed through channels such as derma-cosmetics, phytotherapeutics, and pharmaceuticals, targeting diverse markets with a focus on therapeutic and wellness products.

Avicanna's top competitors include ZYUS Life Sciences, Neocannbio and IMCannabis.

Avicanna offers Medical Cannabis Products, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients.

Yes, Avicanna is publicly traded on TSX under the ticker symbol AVCN.

Avicanna has 3 investors. Key investors include Tasly, Orthogonal Thinker, and Barn Invest.

The ticker symbol of Avicanna is AVCN on TSX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available